Clinical Trials Browser

Cholangiocarcinoma

Gastrointestinal Stromal Tumors

Pancreatic Neoplasms

Neoplasm Metastasis, Cholangiocarcinoma

Leukemia, Myeloid, Acute

Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Solid Tumor, Miscellaneous

Carcinoma, Transitional Cell

Cholangiocarcinoma

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

Cholangiocarcinoma

Hematologic Neoplasms

Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel

Cholangiocarcinoma

Advanced Non Small Cell Lung Cancer

Colorectal Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Locally Advanced Unresectable Gastric Cancer

Pancreatic Neoplasms

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

Gastrointestinal Neoplasms

Gastrointestinal Neoplasms

Breast Neoplasms

Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Clinical Trials

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

PEMIGIST

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

AcSé PEMI

PEGASUS

Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma

FINPROVE

Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

ROME

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant

Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy

A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations

A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients

A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy